Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital

Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cerebral Toxoplasmosis Abscess Brain Abscess Brain Diseases Central Nervous System Diseases Central Nervous System Infections Central Nervous System Parasitic Infections Central Nervous System Protozoal Infections Coccidiosis Immune System Diseases Immunologic Deficiency Syndromes Infections Nervous System Diseases Parasitic Diseases Protozoan Infections Suppuration Toxoplasmosis Toxoplasmosis, Cerebral

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service d'immunologie clinique - Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

Location status: Recruiting

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult (≥18 years)
Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary).
At least one positive toxoplasmosis PCR test (regardless of tissue)

Exclusion criteria

Subject who has expressed opposition to the reuse of their data for scientific research.
HIV positive
Congenital toxoplasmosis
Isolated ocular toxoplasmosis in immunocompetent individuals

Treatment and study plan

Primary outcomes

Overall patient survival rates

Time frame: Up to 1 year

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

Retrospective Descriptive Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital From 2010 to 2023

Acronym: TOXO

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Dec 23, 2025
Registry last updated: Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed